Hematopoietic stem-cell transplantation is potentially curative treatment for malignant and
non-malignant diseases. The development and severity of graft-versus-host disease (GVHD)
is strongly related with post-transplant outcomes. GVHD may at the same time improve
survival by decreasing the risk of disease relapse and increase non-relapse mortality by
causing organ failure and predisposing the recipient to life-threatening infections. Currently
available classifications attempt to separate GVHD into subgroups according to their risk of …